Table 1 |
|||||||||
|
Frequency of FH-autoantibodies and CFHR1 deficiency in patients compared to healthy controls. |
|||||||||
|
Total number of patients and controls |
FH-autoantibody positive individuals |
FH-autoantibody negative individuals |
Odds Ratio for anti-FH positivity in CFHR1 deficiency |
||||||
|
% |
No. |
CFHR1 deficiency No. (%) |
No. |
CFHR1 deficiency No. (%) |
OR |
95% CI |
P-value |
||
|
|
|||||||||
|
LA+ Sweden |
64 |
9.4 |
6 |
5 (83.3) |
58 |
1 (1.7) |
285 |
15.4 to 5,280 |
<0.0001 |
|
Controls Sweden |
64 |
6.3 |
4 |
1 (25.0) |
60 |
1 (1.7) |
20 |
1.0 to 397 |
1.12 |
|
SLE Low SLEDAI, Sweden |
30 |
0.0 |
0 |
0 (0.0) |
30 |
1 (3.3) |
n.a1 |
||
|
Controls Sweden |
30 |
0.0 |
0 |
0 (0.0) |
30 |
0 (0.0) |
n.a. |
||
|
SLE High SLEDAI, Sweden |
30 |
13.3 |
4 |
0 (0.0) |
26 |
1 (3.8) |
2.0 |
0.066 to 54.1 |
1 |
|
Controls Sweden |
30 |
10.0 |
3 |
0 (0.0) |
27 |
1 (3.7) |
6.3 |
0.17 to 231 |
1 |
|
RA Sweden |
97 |
16.5 |
16 |
2 (12.5) |
81 |
5 (6.2) |
2.0 |
0.38 to12.3 |
0.3 |
|
Controls Sweden |
97 |
2.1 |
2 |
0(0.0) |
95 |
1(1.1) |
12.3 |
0.44 to 384 |
1 |
|
RA The Netherlands |
217 |
9.2 |
20 |
0 (0.0) |
197 |
7 (3.6) |
n.a. |
||
|
Controls The Netherlands |
161 |
3.1 |
5 |
0 (0.0) |
156 |
13 (8.3) |
n.a. |
||
|
aHUS Germany |
103 |
11.7 |
12 |
3 (25.0) |
91 |
4 (4.4) |
6.45 |
1.25 to 33.05 |
0.04 |
|
Controls Germany |
20 |
5.0 |
1 |
0 (0.0) |
19 |
0 (0.0) |
n.a. |
||
|
|
|||||||||
|
1n.a., not applicable due to 0% frequency |
|||||||||
|
Foltyn Zadura et al. Arthritis Research & Therapy 2012 14:R185 doi:10.1186/ar4016 |
|||||||||
